Screening for Metabolic Phenotypes
The drug discovery process requires utilizing relevant assays and cellular models. Furthermore, the elimination of drug candidates goes beyond efficacy to reliably predicting toxicity, using relevant models. Researchers are leveraging Agilent Seahorse XF technology to identify potential metabolic targets, as well as validate adverse effects earlier in the drug discovery process.
Learn more about How XF Technology Works
Click to search either the Seahorse XF Publications Database or the Seahorse Cell Reference Database
For Research Use Only. Not for use in diagnostic procedures.